570 related articles for article (PubMed ID: 29195073)
1. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Topper MJ; Vaz M; Chiappinelli KB; DeStefano Shields CE; Niknafs N; Yen RC; Wenzel A; Hicks J; Ballew M; Stone M; Tran PT; Zahnow CA; Hellmann MD; Anagnostou V; Strissel PL; Strick R; Velculescu VE; Baylin SB
Cell; 2017 Nov; 171(6):1284-1300.e21. PubMed ID: 29195073
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Adeegbe DO; Liu Y; Lizotte PH; Kamihara Y; Aref AR; Almonte C; Dries R; Li Y; Liu S; Wang X; Warner-Hatten T; Castrillon J; Yuan GC; Poudel-Neupane N; Zhang H; Guerriero JL; Han S; Awad MM; Barbie DA; Ritz J; Jones SS; Hammerman PS; Bradner J; Quayle SN; Wong KK
Cancer Discov; 2017 Aug; 7(8):852-867. PubMed ID: 28408401
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation.
Seo SK; Jin HO; Woo SH; Kim YS; An S; Lee JH; Hong SI; Lee KH; Choe TB; Park IC
J Thorac Oncol; 2011 Aug; 6(8):1313-9. PubMed ID: 21642861
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
[TBL] [Abstract][Full Text] [Related]
7. The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
Moon EK; Langer CJ; Albelda SM
Ann Am Thorac Soc; 2017 Aug; 14(8):1248-1260. PubMed ID: 28613923
[TBL] [Abstract][Full Text] [Related]
8. Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Yang H; Sun B; Xu K; He Y; Zhang T; Hall SRR; Tan ST; Schmid RA; Peng RW; Hu G; Yao F
EBioMedicine; 2021 Jul; 69():103457. PubMed ID: 34224975
[TBL] [Abstract][Full Text] [Related]
9. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
10. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
[TBL] [Abstract][Full Text] [Related]
12. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells.
Zhang S; Wu K; Feng J; Wu Z; Deng Q; Guo C; Xia B; Zhang J; Huang H; Zhu L; Zhang K; Shen B; Chen X; Ma S
Oncotarget; 2016 Oct; 7(42):68768-68780. PubMed ID: 27634890
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy and Immunotherapy for Lung Cancer.
Naylor EC; Desani JK; Chung PK
Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
[TBL] [Abstract][Full Text] [Related]
17. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
18. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.
Pennell NA
Semin Oncol; 2015 Oct; 42 Suppl 2():S3-10. PubMed ID: 26477472
[TBL] [Abstract][Full Text] [Related]
19. Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.
Conforti F; Pala L; Pagan E; Bagnardi V; De Pas T; Queirolo P; Pennacchioli E; Catania C; Cocorocchio E; Ferrucci PF; Saponara M; Orsolini G; Zagami P; Nicoló E; De Marinis F; Tortora G; Bria E; Minucci S; Joffe H; Veronesi P; Wargo J; Rosenthal R; Swanton C; Mantovani A; Gelber RD; Viale G; Goldhirsch A; Giaccone G
Clin Cancer Res; 2021 Aug; 27(15):4311-4324. PubMed ID: 34016641
[TBL] [Abstract][Full Text] [Related]
20. Dual-Epigenetically Relieving the MYC-Correlated Immunosuppression via an Advanced Nano-Radiosensitizer Potentiates Cancer Immuno-Radiotherapy.
Wang G; Yan J; Tian H; Li B; Yu X; Feng Y; Li W; Zhou S; Dai Y
Adv Mater; 2024 May; 36(19):e2312588. PubMed ID: 38316447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
